glp-1 incretin effect Incretin-based therapy of metabolic disease Cardiovascular effects of Glucagon-like peptide

Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)

Realidad: Existe cierta preocupacin sobre un posible vnculo entre los medicamentos GLP-1 y el riesgo de cncer, pero hasta ahora no hay evidencia slida que lo confirme

The discussion below of Medicare Part D participation in BALANCE reflects implementation details under CMSs original design

Next we investigated stability in human serum

& Petrie, J

Richard Siegel, co-director of the Diabetes and Lipid Center at Tufts Medical Center in Boston